ONCOCROSS

  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

CONTACT US
  • KR
  • EN
  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

  • KR
  • EN
CONTACT US
  • Main
  • News/IR
  • Knowledge Hub

Knowledge Hub

21 Posts
  • 09. Selective killing of circulating tumor cells prevents metastasis and extends survival

    06-18-2026
  • 08. Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer

    06-18-2026
  • 07. Fluorescent cell-selective ablation using an adaptive photodynamic method

    06-18-2026
  • 06. Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression

    06-18-2026
  • 05. Bioluminescence-Activated Deep-Tissue Photodynamic Therapy of Cancer

    06-18-2026
  • 04. Longitudinal Tracing of Spontaneous Regression and Anti-angiogenic Response of Individual Microadenomas during Colon tumorigenesis

    06-18-2026
  • 03. Transcriptome analysis indicates TFEB1 and YEATS4 as regulatory transcription factors for drug resistance of ovarian cancer

    06-18-2026
  • 02. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma

    06-18-2026
  • 01. In vivo imaging of Lgr5-positive cell populations using confocal laser endomicroscopy during early colon tumorigenesis

    06-18-2026
  • 1
  • 2

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
Room 905, 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, Korea (Munjeong-dong, Munjeong Hyundai Knowledge Industry Center 1-2)
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.